• The Company
    • Who we are
    • Partner Portal
  • Meet the Partners
  • Our Approach
  • Portfolio
    • Current Portfolio
    • Historic Portfolio
  • News
  • Contact Us
The Vertical Group
Investing for Innovation

ProteinSimple Launches Multimode Imager with IR Capability

7/24/2013

 
Via ProteinSimple:
Santa Clara, CA, July 24, 2013 — ProteinSimple today introduced the FluorChem R system as the next member of the FluorChem product family. The FluorChem R system is a fully integrated, multimode gel and Western blot imager with chemiluminescent, fluorescent, and infrared detection capabilities. 

The FluorChem R system takes Western blot imaging to the next level by combining three key elements — application flexibility, sensitivity and ease-of-use. Its 8.3 megapixel CCD camera and simple 10.4 inch touch screen interface allow researchers to detect even the faintest band — and get crisp, clear images every time. Like the preceding FluorChem products, it is equipped with an on-board computer and intuitive browser-based Digital Darkroom acquisition and analysis software, so the FluorChem R system is ready to use right out the box.

"The FluorChem R system brings together three detection modes in a single instrument, making it the 'do all' instrument in the gel and blot imaging space today," commented John Proctor, Director of Marketing at ProteinSimple. "The multimode capability of the FluorChem R system will enable researchers to use a broad array of secondary antibodies and dyes without additional instruments or reagents; ultimately maximizing laboratory bench space."

Read more: http://www.proteinsimple.com/news_details.html?id=47&page=news.html

ViaCyte, Inc. raises $10.6 Million in a Private Financing to Support Clinical Development of its Cell Therapy Product for Insulin Dependent Diabetes

7/10/2013

 
Via ViaCyte:
San Diego, California, July 10, 2013 — ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a stem cell-derived cell therapy, announced today that it completed a private equity financing transaction, providing the Company $10.6 million through the sale of Series C-1 Preferred Stock, together with warrants to purchase stock.  The financing, conducted as a rights offering to ViaCyte Series B and C Preferred Stock holders, included the Company’s largest existing investors – Johnson & Johnson Development Corporation, Sanderling Ventures and Asset Management Company (Johnson Trust).

This funding serves as a match for a $10.1 million Strategic Partnership Award (SPA) that was approved last October by the California Institute for Regenerative Medicine (CIRM) to support clinical evaluation of VC-01, ViaCyte’s promising encapsulated cell-therapy product being developed as a transformative therapy for patients with type 1 and insulin-dependent type 2 diabetes.  In addition, ViaCyte may sell additional shares of Series C-1 Preferred Stock and warrants in one or more subsequent closings that may occur during the remainder of 2013.

The Company will use the funds to pursue clinical development of VC-01. VC-01 is a development-stage product that consists of pancreatic precursor cells (designated PEC-01) manufactured through directed differentiation of stem cells sourced from a proprietary human embryonic stem cell line, and encapsulated in a proprietary, immune protective medical device (the ENCAPTRA® device).  When implanted under the skin, the encapsulated cells are designed to further differentiate into insulin and other hormone-producing pancreatic cells that regulate blood glucose in a manner similar or identical to a normal pancreas.

Read more: http://viacyte.com/press-releases/viacyte-inc-raises-10-6-million-in-a-private-financing-to-support-clinical-development-of-its-cell-therapy-product-for-insulin-dependent-diabetes/

Prevent Participant Judy Twist NPR Radio Show Interview about her experience with the program

7/2/2013

 
Via It's Your Health Network:
Judy Twist shares with Lisa her success with the program Prevent. 
 
Prevent is a 16-week online program designed to help people lose weight and reduce their risk of type 2 diabetes. We combine a clinically-proven curriculum with individual mentorship to guide participants toward manageable but powerful goals.

http://omadahealth.com/programs/diabetes-prevention/

Listen here.

    Archives

    December 2020
    December 2019
    November 2019
    October 2019
    August 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    April 2015
    March 2015
    February 2015
    January 2015
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    February 2014
    January 2014
    December 2013
    October 2013
    August 2013
    July 2013
    June 2013
    May 2013
    April 2013
    March 2013
    February 2013
    January 2013

    RSS Feed

© The Vertical Group - info@vertical-group.com
 PO 218, Berkeley Heights, NJ 07922 | (908) 277-3737
PO 5006, San Mateo, CA  94402 | (650) 566-9060
Picture
Website by Custom Dynamics